Loading...
Market
What will be Novo Nordisk's response to the Harvard study on NAION risk by end of 2024?
2
Resolution / Starting Odds
Acknowledge risk and issue warning • 25%
Deny risk and continue marketing • 25%
Initiate further studies • 25%
Discontinue affected products • 25%
Official statements from Novo Nordisk
Story
Harvard Study Reveals Link Between Ozempic, Wegovy and Serious Eye Condition NAION
Jul 3, 2024, 03:06 PM
A new study by Massachusetts Eye and Ear has revealed a potential link between Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. The study indicates that patients prescribed these drugs for diabetes or weight loss had a higher risk of developing NAION than those not on the medication. This research, published on Wednesday, is the first to establish this connection. The findings have raised concerns about the safety of these widely popular weight-loss and diabetes treatments. The study involved 710 type 2 diabetes patients and was conducted in collaboration with Harvard.
View original story
Similar markets
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Yes • 50%
No • 50%
Public apology • 25%
Denial of wrongdoing • 25%
Commitment to improve transparency • 25%
No comment • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No publication • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Focus on improving CagriSema • 25%
Develop a new obesity drug • 25%
Increase investment in marketing existing drugs • 25%
Pursue mergers or acquisitions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Significant price reduction • 25%
Minor price reduction • 25%
No price reduction • 25%
Other • 25%